Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo-controlled trial

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 102-109

  Chen, Wei Ren ^a   Liu, Zhi Ying ^a   Shi, Yang ^a   Yin, Da Wei ^a   Wang, Hao ^a   Sha, Yuan ^a   Chen, Yun Dai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adjuvant therapy; Hypertension; Supplementation; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; NIFEDIPINE; PARATHYROID HORMONE; PLACEBO; VITAMIN D;

ADD ON THERAPY; ADULT; ALLERGY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CHINESE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEART PALPITATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; AGED; BLOOD PRESSURE; CHINA; DIETARY SUPPLEMENT; HYPERTENSION; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHINA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; VITAMIN D;

EID: 84901835731     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.011     Document Type: Article

References (36)

1. Yu J.R., Lee S.A., Lee J.G., Seong G.M., Ko S.J., Koh G., et al. Serum vitamin D status and its relationship to metabolic parameters in patients with type 2 diabetes. Mellitus. Chonnam Med J 2012, 48:108-115.
2. Demir M., Günay T., Özmen G., Melek M. Relationship between vitamin D deficiency and nondipper hypertension. Clin Exp Hypertens 2013, 35:45-49.
3. Chopra S., Cherian D., Jacob J.J. The thyroid hormone, parathyroid hormone andvitamin D associated hypertension. Indian J Endocrinol Metab 2011, 15:354-360.
4. Chalmers J., Arima H., Harrap S., Touyz R.M., Park J.B. Global survey of current practice in management of hypertension as reported by societies affiliated with the International Society of Hypertension. JHypertens 2013, 31:1043-1048.
5. Girerd X., Hanon O., Pannier B., Vaïsse B., Mourad J.J. Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys. Ann Cardiol Angeiol (Paris) 2013, 62:210-214.
6. Wong M.C., Tam W.W., Cheung C.S., Tong E.L., Sek A.C., Cheung N.T., et al. Antihypertensive prescriptions over a 10-year period in a large Chinese population. Am J Hypertens 2013, 26:931-938.
7. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). JHypertens 2013, 31:1281-1357. Task Force Members.
8. Aronson D., Roterman I., Yigla M., Kerner A., Avizohar O., Sella R., et al. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med 2006, 174:626-632.
9. Minoguchi K., Yokoe T., Tanaka A., Ohta S., Hirano T., Yoshino G., et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006, 28:378-385.
10. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
11. Al-Daghri N.M., Alkharfy K.M., Al-Othman A., El-Kholie E., Moharram O., Alokail M.S., et al. Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study. Cardiovasc Diabetol 2012, 11:85.
12. Ortega R.M., Requejo A.M., López-Sobaler A.M. Activity questionnaire. Nutrigui{dotless}'a. Manual of clinical nutrition in primary care 2006, 468. Complutense, Madrid. 1st ed. R.M. Requejo, R. Ortega (Eds.).
13. Energy and protein requirements 1985, World Health Organization (WHO), Report of a joint FAO/WHO/UNU meeting, WHO, Geneva, WHO Tech Rep Ser No 724.
14. Ortega R.M., Requejo A.M., Quintas E., Sánchez-Quiles B., López-Sobaler A.M., Andrés P. Estimated energy balance in female university students: differences with respect to body mass index and concern about body weight. Int J Obes 1996, 20:1127-1129.
15. Larsen T., Mose F.H., Bech J.N., Hansen A.B., Pedersen E.B. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens 2012, 25:1215-1222.
16. Witham M.D., Nadir M.A., Struthers A.D. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. JHypertens 2009, 27:1948-1954.
17. Forman J.P., Scott J.B., Ng K., Drake B.F., Suarez E.G., Hayden D.L., et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 2013, 61:779-785.
18. Forsythe L.K., Livingstone M.B., Barnes M.S., Horigan G., McSorley E.M., Bonham M.P., et al. Effect of adiposity on vitamin D status and the 25-hydroxycholecalciferol response tosupplementation in healthy young and older Irish adults. Br J Nutr 2012, 107:126-134.
19. Sanchez I., Mangoo-Karim R., Stubbs J.R., Yanev G.P., Wetmore J.B. Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD. Int Urol Nephrol 2013, 45:181-189.
20. Alvarez Jessica A., Bush Nikki C., Choquette Suzanne S., Hunter Gary R., Darnell Betty E., Oster Robert A., et al. Vitamin D intake is associated with insulin sensitivity in African American, but not European American, women. Nutr Metab (Lond) 2010, 7:28.
21. Mancia G., Parati G., Bilo G., Choi J., Kilama M.O., Ruilope L.M. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. JHypertens 2011, 29:600-609. TALENT investigators.
22. Mamedov M.N., Kiseleva N.V. Rational approach to selection of antihypertensive therapy in persons with metabolic syndrome: efficacy of monotherapy with spirapril and its combination with retard form of nifedipine. Kardiologiia 2006, 46:26-30.
23. Falcone C., Buzzi M.P., Bozzini S., Boiocchi C., D'Angelo A., Schirinzi S., et al. Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. Mediators Inflamm 2012, 2012:874149.
24. Elliott H.L., Meredith P.A. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. JHum Hypertens 2011, 25:63-70.
25. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. JClin Invest 2002, 110:229-238.
26. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
27. Koroshi A., Idrizi A. Renoprotective effects of vitamin D and renin-angiotensin system. Hippokratia 2011, 15:308-311.
28. Kota S.K., Kota S.K., Jammula S., Meher L.K., Panda S., Tripathy P.R., et al. Renine angiotensin system activity in vitamin D deficient, obese individuals with hypertension: an urban Indian study. Indian J Endocrinol Meta 2011, 15:395-401.
29. Carrara D., Bernini M., Bacca A., Rugani I., Duranti E., Virdis A., et al. Cholecalciferol administration blunts the systemic renineangiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst 2014, 15:82-87.
30. Chen W.R., Liu Z.Y., Shi Y., Yin D.W., Wang H., Sha Y., et al. Relation of low vitamin d to nonvalvular persistent atrial fibrillation in Chinese Patients. Ann Noninvasive Electrocardiol 2014, 19:166-173.
31. Chen W.R., Qian Y.A., Chen Y.D., Shi Y., Yin D.W., Wang H., et al. The effects of low vitamin D on coronary artery disease. Heart Lung Circ 2014, 23:314-319.
32. Savoia C., Schiffrin E.L. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006, 15:152-158.
33. Alvarez J.A., Zughaier S.M., Law J., Hao L., Wasse H., Ziegler T.R., et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 2013, 67:264-269.
34. Rostand S.G., Drüeke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Ki{dotless}dney Int 1999, 56:383-392.
35. Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
36. Witham M.D., Price R.J., Struthers A.D., Donnan P.T., Messow C.M., Ford I., et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension. The VitDISH randomized controlled trial. JAMA Intern Med 2013, 173:1672-1679.